Ultrasound Elastography for Predicting Sinusoidal Obstruction Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to predict sinusoidal obstruction syndrome (SOS), a liver condition that can occur after a bone marrow transplant. It employs ultrasound elastography, a non-invasive imaging technique, to assess its effectiveness in identifying and classifying the severity of SOS. The trial aims to determine the accuracy of this method in early detection of SOS. Individuals undergoing a specific type of bone marrow transplant preparation or those with conditions that increase their risk for SOS may be suitable candidates for this trial. As an unphased study, this trial provides a unique opportunity to contribute to innovative research that could enhance early detection of SOS.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this ultrasound elastography is safe for predicting sinusoidal obstruction syndrome?
Research has shown that ultrasound elastography is a safe procedure, carrying no more risks than a regular ultrasound. One study with 63 patients used this technique to help diagnose sinusoidal obstruction syndrome (SOS) without any safety issues. Commonly used for liver checks, it does not add any extra risk. Overall, ultrasound elastography is well-tolerated and as safe as standard ultrasound tests.12345
Why are researchers excited about this trial?
Researchers are excited about ultrasound elastography for predicting sinusoidal obstruction syndrome because it offers a non-invasive way to assess liver stiffness and detect early signs of this condition. Unlike the current standard, which may require more invasive procedures like liver biopsies, ultrasound elastography is safer and more comfortable for patients. This method provides real-time results, potentially allowing for earlier intervention and better management of the syndrome.
What evidence suggests that ultrasound elastography is effective for predicting sinusoidal obstruction syndrome?
Studies have shown that ultrasound elastography, particularly shear wave elastography (SWE), can help predict sinusoidal obstruction syndrome (SOS). In a study with 63 adults who underwent bone marrow transplants, SWE proved useful in diagnosing SOS. Research indicates that measuring liver stiffness with elastography can detect changes early, possibly even before SOS symptoms appear. In this trial, participants will undergo ultrasound elastography at specific time points to evaluate its effectiveness in predicting and assessing the severity of SOS. These findings suggest that ultrasound elastography might offer a non-invasive method to identify and assess the severity of SOS in patients.12467
Who Is on the Research Team?
Sherwin Chan, MD PhD
Principal Investigator
Children's Mercy Hospital Kansas City
Are You a Good Fit for This Trial?
This trial is for patients undergoing intense pre-transplant treatment (myeloablative conditioning) for stem cell transplant, including those at high risk for liver-related complications post-transplant. It's not suitable for individuals who can't undergo ultrasound elastography due to conditions like an inability to remain still.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-conditioning
Ultrasound elastography performed within two weeks prior to starting conditioning regimen
Conditioning and Monitoring
Ultrasound elastography performed twice per week through Day +30 or discharge
Follow-up
Ultrasound elastography performed every 30 days until Day +100 or discharge
What Are the Treatments Tested in This Trial?
Interventions
- Ultrasound Elastography
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Mercy Hospital Kansas City
Lead Sponsor
Dana-Farber Cancer Institute
Collaborator
University of California, San Francisco
Collaborator
Duke University
Collaborator
University Hospitals Cleveland Medical Center
Collaborator
M.D. Anderson Cancer Center
Collaborator
Boston Children's Hospital
Collaborator
St. Jude Children's Research Hospital
Collaborator
Jazz Pharmaceuticals
Industry Sponsor
Bruce C. Cozadd
Jazz Pharmaceuticals
Chief Executive Officer since 2009
BA in Economics from Yale University, MBA from Stanford University
Dr. Austin
Jazz Pharmaceuticals
Chief Medical Officer since 2023
MD from the Royal College of Surgeons in Ireland
Nationwide Children's Hospital
Collaborator